다발성 경화증 진단 시장 : 전략적 인사이트와 예측(2026-2035년)

The Multiple Sclerosis Diagnostics Market is anticipated to grow at a CAGR of 10.6% from USD 5.09 billion in 2026 to USD 12.58 billion in 2035.

The global multiple sclerosis diagnostics market is undergoing a significant transformation driven by technological innovation and a growing emphasis on early and accurate disease detection. This market encompasses a comprehensive range of imaging systems, laboratory assays, molecular diagnostics, biomarker tests, and neurological assessment technologies. Diagnostic accuracy depends upon the integration of clinical findings, magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, evoked potential testing, and emerging blood-based biomarkers, as no single standalone test definitively confirms the disease. Demand is increasing as healthcare providers emphasize earlier diagnosis to initiate disease-modifying therapies before irreversible neurological damage occurs. Regulatory agencies and neurological societies are continuously updating diagnostic recommendations to incorporate advances in imaging technology, biomarker validation, and artificial intelligence-assisted interpretation that improve clinical decision-making. Strategic investment in precision neurology, digital diagnostics, and minimally invasive biomarker development is strengthening the long-term importance of advanced diagnostic technologies within the global multiple sclerosis care pathway.

Market Drivers

Increasing Prevalence of Multiple Sclerosis

• The growing prevalence of multiple sclerosis is increasing demand for accurate and timely diagnostic solutions because earlier disease identification enables prompt initiation of disease-modifying therapies. Delayed diagnosis contributes to irreversible neurological disability as inflammatory disease activity continues before treatment begins. Healthcare providers are expanding utilization of advanced MRI systems, CSF analysis, and multimodal neurological assessments to improve diagnostic confidence. These developments are strengthening demand for comprehensive diagnostic technologies that support long-term disease management.

Growing Adoption of Advanced MRI Technologies

• Magnetic resonance imaging remains the cornerstone of multiple sclerosis diagnosis because it enables visualization of demyelinating lesions within the brain and spinal cord. Demand is shifting toward high-field MRI systems and advanced imaging protocols as neurologists require greater sensitivity for detecting early inflammatory changes. Conventional imaging approaches often provide limited lesion characterization in complex cases, encouraging healthcare providers to adopt higher-resolution imaging platforms. Continuous technological innovation is improving diagnostic precision while supporting more standardized neurological assessments.

Rising Demand for Early and Accurate Diagnosis

• Earlier diagnosis is becoming increasingly important because disease-modifying therapies provide greater clinical benefit when initiated during the earliest stages of multiple sclerosis. Clinical symptoms frequently overlap with other neurological disorders, creating diagnostic uncertainty that delays treatment decisions. Healthcare organizations are strengthening multidisciplinary diagnostic pathways by integrating imaging findings, laboratory biomarkers, and neurological examinations into comprehensive evaluation protocols. This transition is improving diagnostic confidence while supporting personalized patient management.

Increasing Development of Blood-Based Biomarkers

• Research into blood-based biomarkers is expanding because clinicians require minimally invasive diagnostic tools capable of complementing imaging and CSF analysis. Conventional lumbar puncture procedures remain invasive and may reduce patient acceptance during diagnostic evaluation. Diagnostic companies and academic research institutions are developing neurofilament light chain (NfL) assays and additional biomarker technologies that improve disease monitoring and clinical assessment. Continued biomarker validation is strengthening the future role of precision laboratory diagnostics in multiple sclerosis management.

Market Restraints

• High cost of advanced MRI systems, specialized laboratory testing, and biomarker-based diagnostics limits widespread adoption across resource-constrained healthcare systems. Absence of a definitive standalone diagnostic test requires integration of multiple clinical and laboratory assessments, increasing diagnostic complexity. Limited availability of specialized neurology centers and trained neuroradiology professionals delays timely diagnosis in several developing healthcare markets. Additionally, variability in reimbursement policies for advanced neuroimaging and biomarker testing can hinder routine clinical adoption.

Technology and Segment Insights

By Diagnostic Modality

• Magnetic resonance imaging (MRI) represents the largest diagnostic modality because it remains the primary tool for detecting demyelinating lesions and monitoring disease progression. CSF analysis continues supporting diagnosis when imaging findings require additional clinical confirmation. Blood biomarker tests are gaining increasing attention because they offer minimally invasive disease assessment and facilitate repeated monitoring. Evoked potential tests and optical coherence tomography complement neurological evaluation by detecting functional and structural changes associated with disease progression. Continued integration of multiple diagnostic modalities is strengthening diagnostic accuracy across diverse patient populations.

By Technology

• High-field MRI (3T and above) continues gaining clinical preference because improved image resolution enhances lesion visualization and supports earlier diagnosis. Conventional MRI remains widely utilized across routine neurological practice due to broad availability. Artificial intelligence-assisted imaging is improving lesion detection, segmentation, and standardized image interpretation, reducing variability and enhancing workflow efficiency. Immunoassays and molecular diagnostics are becoming increasingly important because biomarker validation continues expanding precision neurology capabilities. The combined adoption of advanced imaging and laboratory technologies is strengthening comprehensive neurological diagnostic pathways.

By End User

• Hospitals account for the largest share of diagnostic demand because comprehensive neurological evaluation frequently requires advanced imaging infrastructure, multidisciplinary expertise, and specialized laboratory services. Diagnostic laboratories continue expanding biomarker testing capabilities as precision neurology gains clinical importance. Neurology clinics are increasingly adopting advanced imaging referral pathways and digital diagnostic solutions that improve patient management. Academic and research institutes continue driving biomarker discovery and clinical validation studies supporting future innovation in multiple sclerosis diagnostics.

Competitive and Strategic Outlook

• The competitive landscape features major medical technology companies and specialized diagnostic firms. Siemens Healthineers AG differentiates itself through leadership in diagnostic imaging, digital healthcare, and AI-enabled clinical workflow solutions, with a strong portfolio of high-performance MRI systems. GE HealthCare Technologies Inc. maintains a strong position through its broad portfolio of diagnostic imaging systems, digital healthcare solutions, and enterprise imaging platforms. Koninklijke Philips N.V. integrates advanced diagnostic imaging, digital health technologies, and clinical informatics into comprehensive neurological care pathways. Canon Medical Systems Corporation focuses on high-quality imaging performance and clinical innovation in MRI. F. Hoffmann-La Roche Ltd. distinguishes itself through its integrated pharmaceuticals and diagnostics business model, with extensive expertise in molecular and immunodiagnostics. Quest Diagnostics Incorporated leverages one of the largest clinical laboratory networks globally for neurological testing. Thermo Fisher Scientific Inc. provides a broad portfolio spanning molecular biology, analytical instruments, and specialty diagnostics. Abbott Laboratories and Bio-Rad Laboratories contribute through their expertise in immunoassays and molecular diagnostics. QIAGEN N.V. specializes in molecular diagnostics and bioinformatics solutions.
• Strategic developments include increasing integration of artificial intelligence into imaging and diagnostic platforms, expansion of blood-based biomarker portfolios, and development of digital neurology solutions. Companies are forming collaborations with healthcare providers, academic institutions, and research organizations to validate emerging technologies and accelerate commercialization. The market is shifting toward integrated diagnostic ecosystems that combine imaging, laboratory testing, and digital health services into unified clinical workflows.

Conclusion

• The multiple sclerosis diagnostics market is poised for substantial growth, driven by increasing disease prevalence, technological advancements in MRI and biomarkers, and a growing emphasis on early diagnosis. The shift toward multimodal diagnostic pathways combining high-field imaging, blood-based biomarkers, and AI-assisted interpretation is reshaping clinical practice. Companies that successfully integrate imaging systems, laboratory diagnostics, and digital health platforms into comprehensive precision neurology solutions are expected to strengthen their market position. Ongoing regulatory support, biomarker validation, and expanding healthcare infrastructure across emerging economies will further accelerate innovation and market adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Overview
• 1.2 Market Snapshot
• 1.3 Key Findings
• 1.4 Analyst Insights
• 1.5 Strategic Recommendations

2. Research Methodology

• 2.1 Research Objectives
• 2.2 Market Definition
• 2.3 Research Design
• 2.4 Data Collection Methodology
• 2.5 Forecasting Model
• 2.6 Assumptions and Limitations

3. Market Overview

• 3.1 Introduction to Multiple Sclerosis Diagnostics
• 3.2 Evolution of Diagnostic Technologies
• 3.3 Clinical Diagnosis Workflow
• 3.4 Diagnostic Ecosystem
• 3.5 Market Size and Forecast (2026-2035)
• 3.6 Key Stakeholders

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities

5. Industry Landscape

• 5.1 Supply Chain Analysis
• 5.2 Industry Value Chain Analysis
• 5.3 Pricing Analysis
• 5.4 Technology Landscape
• 5.5 Ecosystem Analysis
• 5.6 Porter's Five Forces Analysis

6. Innovation Landscape

• 6.1 Artificial Intelligence in MRI Interpretation
• 6.2 Neurofilament Light Chain (NfL) Biomarker Development
• 6.3 Digital Neurology Platforms
• 6.4 Cloud-Based Image Analysis
• 6.5 Machine Learning in Lesion Detection
• 6.6 Future Diagnostic Technologies

7. Regulatory Landscape

• 7.1 United States
• 7.2 Europe (IVDR)
• 7.3 Japan
• 7.4 China
• 7.5 Australia
• 7.6 Regulatory Comparison Analysis

8. Market Landscape Analysis

• 8.1 Competitive Benchmarking
• 8.2 Company Market Positioning
• 8.3 Strategic Developments
• 8.4 Mergers & Acquisitions
• 8.5 Partnerships & Collaborations
• 8.6 New Product Launches

9. Market Segmentation

• 9.1 By Diagnostic Modality
  • 9.1.1 Magnetic Resonance Imaging (MRI)
  • 9.1.2 Cerebrospinal Fluid (CSF) Analysis (Lumbar Puncture)
  • 9.1.3 Blood Biomarker Tests
  • 9.1.4 Evoked Potential Tests
  • 9.1.5 Optical Coherence Tomography (OCT)
  • 9.1.6 Others
• 9.2 By Technology
  • 9.2.1 Conventional MRI
  • 9.2.2 High-field MRI (3T & Above)
  • 9.2.3 AI-Assisted Imaging
  • 9.2.4 Immunoassays
  • 9.2.5 Molecular Diagnostics
  • 9.2.6 Others
• 9.3 By End User
  • 9.3.1 Hospitals
  • 9.3.2 Diagnostic Laboratories
  • 9.3.3 Neurology Clinics
  • 9.3.4 Academic & Research Institutes

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
  • 10.1.3 Mexico
• 10.2 Europe
  • 10.2.1 Germany
  • 10.2.2 United Kingdom
  • 10.2.3 France
  • 10.2.4 Italy
  • 10.2.5 Spain
  • 10.2.6 Rest of Europe
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Australia
  • 10.3.6 Rest of Asia Pacific
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Argentina
  • 10.4.3 Rest of Latin America
• 10.5 Middle East & Africa
  • 10.5.1 GCC
  • 10.5.2 South Africa
  • 10.5.3 Rest of Middle East & Africa

11. Country-Level Analysis

• 11.1 United States
• 11.2 Germany
• 11.3 United Kingdom
• 11.4 France
• 11.5 China
• 11.6 Japan
• 11.7 India
• 11.8 Brazil

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Dashboard
• 12.3 Strategic Positioning Matrix
• 12.4 Product Portfolio Analysis
• 12.5 SWOT Analysis

13. Company Profiles

• 13.1 Siemens Healthineers AG
• 13.2 GE HealthCare Technologies Inc.
• 13.3 Koninklijke Philips N.V.
• 13.4 Canon Medical Systems Corporation
• 13.5 F. Hoffmann-La Roche Ltd.
• 13.6 Quest Diagnostics Incorporated
• 13.7 Thermo Fisher Scientific Inc.
• 13.8 Abbott Laboratories
• 13.9 Bio-Rad Laboratories, Inc.
• 13.10 QIAGEN N.V.
• 13.11 Danaher Corporation
• 13.12 Sysmex Corporation
• 13.13 Fujifilm Holdings Corporation
• 13.14 Illumina, Inc.
• 13.15 Revvity, Inc.

14. Market Forecast

• 14.1 Market Revenue Forecast (2026-2031)
• 14.2 Forecast by Diagnostic Modality
• 14.3 Forecast by Technology
• 14.4 Forecast by End User
• 14.5 Forecast by Region

15. Investment & Growth Opportunities

• 15.1 Emerging Investment Areas
• 15.2 AI-Based Diagnostic Solutions
• 15.3 Biomarker Innovation Opportunities
• 15.4 Strategic Partnership Opportunities
• 15.5 Emerging Market Expansion

16. Future Market Outlook

• 16.1 Future Trends in MS Diagnostics
• 16.2 Next-Generation Biomarker Development
• 16.3 AI-Driven Clinical Decision Support
• 16.4 Precision Neurology Outlook
• 16.5 Long-Term Market Opportunities